Business Wire

GIGABYTE Showcases Comprehensive AI Computing Portfolio at MWC 2025, Leading Industry Transformation from Development to Deployment

Share

GIGABYTE, a global leader in computing innovation and technology, will showcase its full-spectrum AI computing solutions that bridge development to deployment at MWC 2025, taking place from March 3-6.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250223099238/en/

GIGABYTE Showcases Comprehensive AI Computing Portfolio at MWC 2025, Leading Industry Transformation from Development to Deployment (Photo: Business Wire)

“AI+” and “Enterprise-Reinvented” are two of the themes for MWC. As enterprises accelerate their digital transformation and intelligent upgrades, the transition of AI applications from experimental development to democratized commercial deployment has become a critical turning point in the industry. Continuing its "ACCEVOLUTION" initiative, GIGABYTE provides the comprehensive infrastructure products and solutions spanning cloud-based supercomputing centers to edge computing terminals, aiming to accelerate the next evolution and empower industries to scale AI applications efficiently.

Development: High-Performance Scalable Parallel Computing Laying the Foundation for AI Models

GIGABYTE’s close partnerships with industry leaders ensure its position of first-to-market brand offering the most diverse range of AI servers. In response to the continuous evolution of AI chips, GIGABYTE uses its flagship HGX servers design and releases next-gen G893 AI servers to support cutting-edge GPUs like NVIDIA B200, AMD MI325X, and Intel Gaudi-3, with capacity for 12 full-height accelerator cards and full redundant power supply. These servers can be ideal for both cluster operations in data centers and standalone enterprise deployments, advancing intelligent transformation.

GIGABYTE has also launched GIGAPOD, a cluster computing solution for cloud AI data centers, offering a one-stop scalable solution for large AI model training. GIGAPOD can support G893 AI servers while integrating computing and network hardware in a complete rack-level solution, along with optional operating systems and software. The solution encompasses comprehensive services from design, deployment to validation, ensuring efficient AI data center operations. The model showcased at MWC supports NVIDIA B200 and features G4L3 server rack with DLC liquid cooling technology, demonstrating GIGABYTE's readiness for expanding future-proof AI development.

Deployment: Low Latency, Energy Efficiency, and Flexible Edge Computing Solutions Connecting AI's Last Mile

As large models mature, AI is evolving from cloud development toward edge deployment and application, requiring servers and computing solutions focused on flexible implementation and ROI. GIGABYTE's general purpose R-series servers employ CXL technology, which leverages PCIe lanes to coexist with DDR5 memory, enabling memory and resource sharing, enhance bandwidth support, and increase overall operation efficiency with lower space requirements and deployment costs. The X-series servers featuring NVIDIA MGX™ modular design, allowing seamless upgrades to NVIDIA's next-generation GPU platforms by simply replacing the baseboard, ensuring long-term value for enterprise technology investments and facilitating flexible deployment across various edge AI scenarios like smart cities and industrial IoT.

At MWC, GIGABYTE is also showcasing several edge-optimized servers, including EIA-standard edge computing servers with AMD and Intel CPUs, and debuting a new 3U blade server. These servers offer computing options with varying densities and architectures to meet the diverse requirements of edge applications, helping users reduce AI deployment costs and energy consumption while improving computing efficiency.

Through its strong R&D capabilities and close industry partnerships, GIGABYTE has established a complete AI computing ecosystem from cloud to edge. With a comprehensive product line ranging from data center cluster computing solutions to edge computing deployment options, GIGABYTE is a “Game Changer” that enables AI innovation across enterprises and research institutions of all sizes. As AI applications continue to expand, GIGABYTE's full product lineup, supporting the latest generation of computing chips, along with evolving hardware design, software integration, system management, and deployment services, continues to establish a solid foundation for a smarter, more efficient, and scalable future.

More Information https://www.gigabyte.com/Events/MWC

View source version on businesswire.com: https://www.businesswire.com/news/home/20250223099238/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye